Sight Sciences, Inc. (SGHT) intrinsic value & 10-year financials
Sight Sciences, Inc. (SGHT) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 7 fiscal years revenue grew 22.9% a year to $77.4M, with an average return on invested capital of -386.4%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $8.28
- Market cap
- $431.8M
- Revenue (FY2025)
- $77.4M
- Revenue growth (7-yr CAGR)
- 22.9%
- ROIC (10-yr avg)
- -386.4%
- Free cash flow (FY2025)
- -$29.9M
SGHT 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $77.4M | -$38.4M | -$0.74 | -$29.9M | -48.0% | -385.0% |
| FY2024 | $79.9M | -$51.5M | -$1.03 | -$22.7M | -63.3% | -422.5% |
| FY2023 | $81.1M | -$55.5M | -$1.14 | -$48.0M | -70.7% | -441.4% |
| FY2022 | $71.3M | -$86.2M | -$1.80 | -$76.9M | -117.7% | -1187.5% |
| FY2021 | $49.0M | -$63.0M | -$2.36 | -$53.4M | -105.2% | 91.0% |
| FY2020 | $27.6M | -$34.7M | — | -$33.1M | -116.5% | 27.2% |
| FY2019 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Sight Sciences, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Sight Sciences, Inc. has earned high returns on invested capital, averaging 15.6% ROIC over the available history. High ROIC is consistent with a durable franchise, but it is not by itself proof of an economic moat.
Sight Sciences, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Sight Sciences, Inc. is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-24.58 per share.